Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo To File ANDA For Lanoxin Elixir, Requests Two-Years For Approval

Executive Summary

GlaxoSmithKline plans to file an ANDA for Lanoxin Elixir using the tablet formulation of its cardiac drug Lanoxin (digoxin) as its reference drug.

You may also be interested in...



Digoxin Timelines: Unapproved Tablets Can Remain 30 Days, Elixirs Two Years

Roxane Laboratories plans to submit an NDA for its digoxin elixir product in November, the company says

Digoxin Timelines: Unapproved Tablets Can Remain 30 Days, Elixirs Two Years

Roxane Laboratories plans to submit an NDA for its digoxin elixir product in November, the company says

Digoxin Marketing Rule Should Postpone Effective Date Two Years - Jerome

FDA should postpone a digoxin marketing final rule effective date two years to allow sufficient time for manufacturers to file and receive NDA or ANDA approval for the cardiac drug, Jerome Stevens said in recent comments to the agency.

Related Content

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel